光庫科技(300620.SZ):鈮酸鋰高速調製器芯片研發及產業化募投項目已基本完成裝修工程和研發中心、封裝測試中心設備調試及驗收
格隆匯11月13日丨有投資者於投資者互動平台向光庫科技(300620.SZ)提問,“公司遲遲不官宣薄膜鈮酸鋰調製器項目投產,是否説明今年4萬片生產計劃即將落空?”,公司回覆稱,公司鈮酸鋰高速調製器芯片研發及產業化募投項目已基本完成裝修工程和研發中心、封裝測試中心設備調試及驗收,目前正在進行新產品研發及芯片生產中心設備採購、人員招聘和工藝平台搭建。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.